- Coordinator
- Fundacio Institut De Bioenginyeria De Catalunya, Spain
- Runs
- 1 December 2025 to 31 May 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101248631
What the project is doing
In the project's own words, from its summary on CORDIS.
Solid tumours frequently develop resistance to therapies, leading to treatment failure. This resistance arises from the complex interplay between heterogeneous cancer cell populations and their microenvironment, driving tumour evolution and local adaptation. Current drug discovery pipelines fall short in addressing this complexity. In this ERC-PoC, we will develop EVOaware, a groundbreaking platform that integrates genome editing, spatial barcoding, high-throughput drug screening, multimodal spatial omics, and spatial pattern analysis, to address the critical challenge of therapeutic resistance in cancer from the lens of evolution.
Ultimately, EVOaware will accelerate the discovery and development of novel cancer therapies, leading to improved patient outcomes.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Institut De Bioenginyeria De Catalunya | Barcelona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI